GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UC-MSCs overview
The therapeutic candidate is under development for the treatment of severe knee osteoarthritis. The therapeutic candidate comprises of umbilical cord (UC)-derived mesenchymal stem cells (MSCs). It is administered by intravenous and intra-articular route.
The therapeutic candidate was also under development for the treatment of diabetic nephropathy and pneumonia caused by coronavirus disease 2019 (COVID-19).
For a complete picture of UC-MSCs’s drug-specific PTSR and LoA scores, buy the report here.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
